Avadel Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Provided By GlobeNewswire
Last update: Nov 12, 2024
-- Generated $50.0 million in net revenue from sales of LUMRYZ™ --
--2,300 patients on LUMRYZ as of September 30th, including 700 patients that initiated therapy in the quarter --
Read more at globenewswire.com
